Bio-Path interim Phase 2 data: 75% CR/CRh/CRi in newly diagnosed AML with prexigebersen combo

BIO-PATH HOLDINGS, INC.

Cohort 1 (newly diagnosed): 15/20 evaluable patients achieved CR/CRh/CRi; median age 75, adverse-risk or secondary AML.
Cohort 2 (relapsed/refractory): 55% of evaluable patients (12/23) achieved CR/CRh/CRi with same triple combination.
Most common severe adverse events: febrile neutropenia (26%) and sepsis (5%); safety consistent with backbone therapy.
Company to continue enrollment up to 98 evaluable for Cohort 1 and 54 for Cohort 2.
Results presented at EHA Congress 2024; CEO highlights potential as additional AML treatment option.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.